Resolution of Secukinumab/Guselkumab-Induced Long-Term Paradoxical Eczematous Eruptions After Switching to Tildrakizumab Treatment.
Miyagawa F, Minami Y
Journal of DermatologyIn the feed 7 Sep 2026, published online 7 Sep 2026, issue 2026 Sep 07, added to PubMed 7 Sep 2026
Topics: Atopic dermatitis & eczema
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42703755 · DOI 10.1111/1346-8138.70494